Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Canaccord Genuity Downgrades Bioventus to Hold

Canaccord Genuity Downgrades Bioventus to Hold

Canaccord Genuity analyst Kyle Rose downgrades Bioventus (NASDAQ:BVS) from Buy to Hold.

byBenzinga Newsdesk

November 9, 2022

1 minute read

Canaccord Genuity analyst Kyle Rose downgrades Bioventus (NASDAQ:BVS) from Buy to Hold.

Hedge Funds Get Squeezed As Bond Bulls Roar Back On Fed’s Dovish Tone

By Piero Cingari

November 6, 10:50 AM

Hedge funds have been on the wrong side of the Treasury market, extending short positions on Treasuries to a record high.

TLT

What’s Going On With Nvidia Stock Wednesday?

By Anusuya Lahiri

December 13, 1:13 PM

Nvidia Corp (NASDAQ: NVDA), apart from expanding its presence across countrie

AMD

Amneal Pharmaceuticals Stock Gaines: It Raised FY23 Outlook On Prescription Trends, Pricing Levels Strength

By Vandana Singh

August 4, 9:38 AM

Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $599 million, an increase of 7% Y/Y, beating the consensus of $5

AMRX

Why Cyngn Stock Is Down Nearly 50%

By Henry Khederian

December 8, 12:58 PM

Cyngn Inc (NASDAQ: CYN) shares are trading lower by 48% to $0.21 during Friday's session after the company announced it priced its public stock offering at around $5.0 million before expenses.

CYN

Canaccord Genuity Downgrades Bioventus to Hold

Related Posts

Hedge Funds Get Squeezed As Bond Bulls Roar Back On Fed’s Dovish Tone

What’s Going On With Nvidia Stock Wednesday?

Amneal Pharmaceuticals Stock Gaines: It Raised FY23 Outlook On Prescription Trends, Pricing Levels Strength

Why Cyngn Stock Is Down Nearly 50%